vida: extract claims from 2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct

- Source: inbox/queue/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-04-23-science-hedonic-eating-dopamine-glp1.md
 scope: causal
 sourcer: Zhenggang Zhu, Scott M. Sternson et al., Janelia Research Campus
 supports: ["Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated"]
-related: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated"]
+related: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement"]
 ---
 
 # The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
 
 The study identifies the precise neural circuit mediating hedonic eating: periLC_VGLUT2 → VTA_VGAT ⊣ VTA_DA → NAc dopamine. This circuit encodes palatability and drives consumption beyond homeostatic need. GLP-1 receptor agonists work by pharmacologically suppressing this circuit's responsiveness. This finding dissolves the behavioral-biological dichotomy for obesity: what appears as a 'behavioral' pattern (eating highly palatable food despite satiety) is the direct output of a specific dopamine reward circuit. However, the circuit is continuously activated by environmental triggers—engineered food palatability. The implication is that behavioral factors (food environment, food engineering) remain primary DRIVERS even though the mechanism is biological, because they continuously activate the biological system. Pharmacological intervention addresses the circuit but must be continuous because the triggering environment is continuous. This reframes the 'behavioral vs. clinical' debate: they are not competing explanations but different levels of a single causal chain where environmental factors activate biological circuits that produce behavioral patterns.
+
+
+## Supporting Evidence
+
+**Source:** Hendershot et al., JAMA Psychiatry 2025, n=48 RCT
+
+First Phase 2 RCT showing semaglutide produces large-range effect sizes (Cohen d > 0.80) on alcohol consumption and craving in adults with AUD through VTA dopamine reward circuit suppression. The dose-response relationship (small effects at 0.25mg, large effects at 0.5mg+) establishes biological mechanism rather than behavioral confounding. This demonstrates a clinical intervention addresses a traditionally 'behavioral' condition through pharmacological modulation of reward circuitry.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -32,3 +32,10 @@ The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA
 **Source:** Annals of Internal Medicine 2024, target trial emulation + exenatide RCT
 
 Target trial emulation (real-world data) shows semaglutide associated with significantly lower risk of medical encounters for tobacco use disorder diagnosis compared with other antidiabetes medications, with strongest effect vs. insulins. Phase 2 RCT (exenatide + NRT) showed increased smoking abstinence vs. placebo + NRT, with reduced cravings and withdrawal symptoms. However, dulaglutide + varenicline RCT showed null result, likely due to ceiling effect (adding GLP-1 to already-effective varenicline). Mechanism consistent with VTA dopamine pathway modulation. This extends the reward circuit claim to a third substance type (tobacco), though evidence is mixed compared to AUD and obesity.
+
+
+## Supporting Evidence
+
+**Source:** Hendershot et al., JAMA Psychiatry 2025
+
+Phase 2 RCT (n=48, 9 weeks) showed dose-dependent effects on alcohol use disorder: small-to-medium effects at 0.25mg escalating to large effect sizes (Cohen d > 0.80) at 0.5mg for heavy drinking days and drinks per drinking day. Laboratory self-administration showed β=−0.48 for grams consumed (p=0.01) and β=−0.46 for peak BrAC (p=0.03). Alcohol craving reduced significantly (β=−0.39, p=0.01). Cigarette consumption in smokers (n=13) also reduced significantly (p=0.005), suggesting broad reward circuit effects.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "Phase 2 RCT shows dose-dependent effects escalating from small (0.25mg) to large (0.5mg+) with Cohen d > 0.80 for heavy drinking reduction"
+confidence: experimental
+source: Hendershot et al., JAMA Psychiatry 2025, n=48 Phase 2 RCT
+created: 2026-04-24
+title: Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
+agent: vida
+sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
+scope: causal
+sourcer: Hendershot CS et al.
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial"]
+---
+
+# Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
+
+A 9-week double-blind RCT (n=48) demonstrated that semaglutide produces clinically significant reductions in alcohol consumption through the same VTA dopamine reward circuit mechanism that drives its metabolic effects. The trial showed dose-response escalation: small-to-medium effects at 0.25mg (weeks 1-4), but large effect sizes (Cohen d > 0.80) at 0.5mg (weeks 5-8) for both heavy drinking days and drinks per drinking day. Laboratory alcohol self-administration showed medium-large effects (β=−0.48 grams consumed, p=0.01; β=−0.46 peak BrAC, p=0.03). Weekly alcohol craving showed significant reduction (β=−0.39, p=0.01). The dose-response relationship is critical evidence: if this were placebo effect or behavioral confounding, effect size would not systematically increase with dose. The mechanism is biologically grounded—semaglutide suppresses VTA dopamine activity, the same pathway mediating food reward and hedonic eating. Notably, the trial also found significant cigarette reduction in the smoker subgroup (n=13, p=0.005), suggesting broad reward circuit effects beyond alcohol. Limitations: Phase 2 only, 9-week duration, non-treatment-seeking participants with moderate AUD severity, and 1.0mg dose reached only in final week. No abstinence endpoints measured. Phase 3 trials now underway.

inbox/archive/health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md

@@ -7,9 +7,12 @@ date: 2025-02-12
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, semaglutide, alcohol-use-disorder, AUD, addiction, reward-circuit, VTA-dopamine, RCT, Phase-2, behavioral-health]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content